Abstract. The overall survival rate of patients with non-small cell lung cancer (NSCLC) following resection remains poor due to the high rates of recurrence and metastasis. The investigation of novel biomarkers is clinically necessary to improve treatment strategies. Multidrug resistance-associated protein 1 (MRP1) and platelet count are linked to a poor prognosis in various types of cancer. However, it is unknown whether MRP1 or platelet count is a suitable prognostic indicator of NSCLC. In the present study, 427 patients with operable NSCLC were enlisted. The association of MRP1 expression and platelet count with clinical pathological factors and patient outcome was evaluated. MRP1 expression was found to be significantly associated with sex, histological type and tumor differentiation, while platelet count was significantly associated with smoking behavior, histological type and clinical stage. Platelet count was significantly higher in patients with negative MRP1 expression than in those with positive MRP1 expression. Survival analysis indicated that there was no association between MRP1 expression and disease-free survival (DFS) or overall survival (OS) time. In the patients with no lymph node metastasis, the OS time was significantly longer in patients with positive MRP1 expression than in those with negative expression. However, in the patients with lymph node metastasis, the DFS time was significantly shorter in patients with positive MRP1 expression than in those with negative expression. There was an association between the platelet count and DFS and OS times, which were significantly longer in patients with a normal platelet count than in those with thrombocytosis. In conclusion, MRP1 expression and platelet count are valuable independent prognostic biomarkers for survival in operable
Introduction
Lung cancer is one of the most common malignancies globally, with non-small cell lung cancer (NSCLC) accounting for the main type, exhibiting a high mortality rate and poor prognosis (1) . The management techniques for NSCLC include surgery, radiotherapy and chemotherapy; however, they exhibit limited effectiveness for NSCLC. Radical surgery has been the standard treatment for early-stage NSCLC. However, patients with similar stages and histological classifications have markedly different survival outcomes (2) . The following resection remains poor due to the high rate of recurrence and metastasis. The prognosis of NSCLC is predominantly based on the Tumor-Node-Metastasis (TNM) staging system, but TNM staging is not able to accurately predict clinical prognosis (3, 4) . Numerous promising biomarkers have been evaluated as potential prognosis predictors of NSCLC; however, none of them have been proven effective for clinical use. Therefore, investigation of novel biomarkers is clinically necessary to improve treatment strategies.
Multidrug resistance (MDR)-associated protein 1 (MRP1) is a member of the ATP-binding cassette membrane transporter family of proteins. MRP1 is primarily expressed in the basolateral membrane of epithelial cells, and governs the absorption and disposition of a wide variety of endogenous and exogenous substrates (5, 6) . MRP1 is implicated in MDR and accommodates the efflux of conventional cytotoxic anticancer agents (7) . Overexpression of MRP1 has been associated with drug resistance and poor outcome in lung, breast and gastric cancer cells and patients (8) (9) (10) (11) (12) (13) .
Platelets serve a multifaceted role in blood clotting, inflammatory response, fibrinolysis and neoplasia. Interactions between tumor cells and platelets are associated with tumor aberrant angiogenesis, invasion and metastasis (14, 15 (16) (17) (18) (19) (20) . However, due to variance in study design and sample size, these studies have reported inconsistent results. It is therefore unknown whether MRP1 or platelet count is a suitable prognostic indicator of NSCLC. In the present study, a retrospective clinical analysis was designed to investigate the prognostic impact of MRP1 and platelet count on the patients' characteristics and survival in those with operable NSCLC. (21) . The tumor stage was defined according to the seventh edition of the TNM classification (4) . The protocol of present study was approved by the Institutional Review Board of Zhejiang Cancer Hospital. All patients provided written informed consent prior to surgery.
Materials and methods

Patients
Blood samples (3 ml) were obtained from each patient prior to surgery. Platelet count was measured using the XE2100 automatic hematology analyzer (Sysmex Co., Tokyo, Japan). A platelet count of <300x10 9 /l was regarded as normal, while a count of >300x10 9 /l was defined as thrombocytosis, according to the manufacturer's protocols.
All patients underwent radical resection of pulmonary carcinoma and radical mediastinal lymph node dissection. All patients received standardized follow-up at a 3-month interval until October 30, 2016 . Among the 427 patients, 225 relapsed during the follow-up, with 200 mortalities, while 15 patients had no record of distal metastasis and 19 patients had no record of overall survival.
Tissue microarray (TMA). TMA blocks were obtained from 427 patients with 1.0-mm diameter representative regions used for each case. Hematoxylin and eosin (H&E) slides (5-mm) were used to identify and mark out representative areas of tumor tissue. The cores were carefully selected from H&E stained sections and inserted into new paraffin blocks using Tissue Arrayer Minicore (Alphelys, Plaisir, France).
Immunohistochemistry (IHC).
Samples were fixed in 4% paraformaldehyde solution at 4˚C for 24 h, embedded in paraffin and cut into 15-µm serial sections. Routine hematoxylin and eosin staining was performed (hematoxylin staining for 5 min and eosin staining for 2 min, both at room temperature). Then the sections were deparaffinized with xylene, and washed using 100, 90 and 70% ethanol, then distilled water. The sections (15 µm thick) were primed for antigen retrieval in citrate buffer (pH 6.0) using microwave heating for a 5-min cycle. Sections were incubated with primary antibody against MRP1 (dilution, 1:200; cat. no. 72202; Cell Signaling Technology, Inc., Danvers, MA, USA) overnight at 4˚C, followed by incubation with biotin labeled goat anti-mouse IgG and horseradish peroxidase-conjugated streptavidin secondary antibody (dilution, 1:500; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) for 1 h at room temperature, stained with 5 mg/ml DAB (Dako Cytomation; cat no. GK346810; Dako; Agilent Technologies, Inc., Sana Clara, CA, USA) for 10 min at room temperature and counterstained with hematoxylin for 2 min at room temperature according to the manufacturer's protocol. The slides were scored according to staining intensity as follows: 0, negative (-); 1, weak positive (+); 2, positive (++), and 3, strong positive (+++). The percentage of positive cells were scored from 0-3 as follows: 0, <5%; 1, 5-25%; 2, 25-50%, and 3, >50%. The final IHC score was a result of multiplying the two scores, with a score of 0 indicating a negative expression and a score of 1-3 indicating a positive expression.
Statistical analysis.
A one-way analysis of variance and χ 2 test were performed to evaluate the association between the clinicopathological variables and MRP1 expression. DFS and OS were analyzed by Kaplan-Meier curves and log-rank test. All the statistical calculations were performed using SPSS 15.0 (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference. Association between MRP1 expression and patient characteristics. The expression of MRP1 protein was localized in the cytoplasm (Fig. 1) . Among the 427 patients, there were 208 (48.7%) patients with positive or strong-positive MRP1 expression and 219 (51.3%) patients with weak-positive or negative MRP1 expression. MRP1 expression was significantly associated with histological type and tumor differentiation, and there was a statistically significant difference between the expression of MRP and the count of PTL (Table I) . However, sex, stage, lymph node metastasis, family history, smoking and alcohol intake history did not have significant association with MRP1 expression (Tables I and II) .
Results
Characteristics of patients.
Association between platelet count and patient characteristics.
The platelet count in all 427 patients range from 67 to 704x10 9 /l. A total of 375 patients (87.8%) had a normal platelet count (<300x10 9 /l) and 62 (14.5%) had thrombocytosis (>300x10 9 /l). The number of platelets was analyzed using a T-test, and patients with platelet numbers higher compared with the normal value were grouped into the high group, and those with lower platelet numbers compared with the normal value were grouped into the low group. A χ 2 test was performed with pathological data. Platelet count was significantly associated with smoking behavior (P=0.041), histological type (P=0.039), clinical stage (P=0.007) and lymph node metastasis (P=0.003) (Table III) . Platelet count was significantly higher in patients of stage III compared with those of stage I-II (P=0.021), in patients with lymph node metastasis than in those with no lymph node metastasis (P=0.014) and in smokers than in non-smokers (P=0.017). Other factors, including age, sex, family history, alcohol intake history and tumor differentiation, did not have a significant association with platelet count (Table IV) . Furthermore, platelet count was significantly higher in patients with negative MRP1 expression than in those with positive MRP1 expression (Fig. 2) .
Association of MRP1 expression with survival. There was no association between MRP1expression and OS (P=0.441) or DFS (P=0.656) according to Kaplan-Meier analysis and log-rank test (Fig. 3A and D) . However, in the patients with no lymph node metastasis, the OS time was significantly longer in patients with positive MRP1 expression than in those with negative expression (P=0.009) (Fig. 3B) . Notably, in the patients with lymph node metastasis, the DFS time was significantly shorter in patients with positive MRP1 expression than in those with negative expression (P=0.022) (Fig. 3F) (Table V) . Table I . Multidrug resistance-associated protein 1 protein expression with multivariate analysis of prognosis in patients with non-small cell lung cancer. 
MRP1 expression
Patients, n (%) Negative, n (%) Positive, n (%) P-value Figure 1 . Expression of MRP1 protein was localized in the cytoplasm (top panels: magnification, x200; scale bars, 100 µm; bottom panels: magnification, x400; scale bars, 50 µm). IHC, immunohistochemistry; MRP1, multidrug resistance-associated protein 1.
Association of platelet count with survival.
There was an association between the platelet count and OS (P=0.008) or DFS (P=0.025) according to Kaplan-Meier analysis and log-rank test ( Fig. 4A and D) . The DFS and OS times were significantly longer in patients with a normal platelet count (<300x10 9 /l) than in those with thrombocytosis (>300x10 9 /l). There was no association between the platelet count and survival for the presence and absence of lymph node metastasis (Fig. 4B, C, E and F) .
Discussion
MRP1 has previously been evaluated and is known to serve an important role in MDR in vitro (22) (23) (24) . MRP1 has also been associated with a poor outcome in NSCLC patients (25, 26) .
Preclinical studies showed that MRP1 protein levels correlated with the resistance to chemotherapeutic agents in NSCLC cell lines, including SK-MES-1, A549, Calu-1, Calu-6, SW-900, SK-LU-1, SK-Luci-6, and SW-1573 (23, 24) . Although high levels of MRP1 expression are frequently observed in the specimens of NSCLC patients, the predictive value of MRP1 expression remains a controversial issue (25) (26) (27) (28) (29) . Certain previous studies reported that patients with NSCLC with high MRP1 expression had a poorer prognosis than those with low MRP1 expression (25, 27) . However, another study indicated that high MRP1 expression contributed to longer OS times in NSCLC patients (27) . It was also reported that there was no association between MRP1 expression and survival in advanced-stage NSCLC patients Table III . Association of PLT level with clinicopathological factors in patients with non-small cell lung cancer. following platinum-based chemotherapy (28) , and another study confirmed that no significant association between MRP1 expression and OS time was observed in completely resected NSCLC patients (29) . In the present study, it was found that MRP1 expression was significantly associated with sex, histological type and tumor differentiation. There was no association between MRP1 expression and DFS. However, in the patients with no lymph node metastasis, the OS time was significantly longer in patients with positive MRP1 expression than in those with negative expression (P=0.009). Notably, in the patients with lymph node metastasis, the DFS time was significantly shorter in patients with positive MRP1 expression than in those with negative expression. The differences between the present study and previous studies may be due to different experimental detective Table IV . Platelet level with multivariate analysis of prognosis in patients with non-small cell lung cancer. methodologies and sample types. The present results suggest that MRP1 is a predictive factor for the survival of NSCLC patients.
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Platelets serve a critical role in tumor progression and metastasis. Studies have confirmed the association between platelets and tumor biology. Platelets act as an important regulator in physiological processes; however, angiogenesis is associated with tumor growth and metastasis (14, 30, 31) . Platelets promote the hematogenous metastasis process by arresting tumor cells within the organ vasculature (32, 33) . Meanwhile, tumor cells have the ability to aggregate platelets, leading to tumor cell-induced platelet aggregation that allows tumor cells to evade immune surveillance (34) . It has been indicated that anti-platelet drugs, including heparin or warfarin, exert antitumor effects in vivo and in vitro (35) . Clinical studies have shown that the risk of venous thrombosis in NSCLC patients is higher than that in tumor-free patients (36) and that high platelet count is correlated to a worse prognosis in NSCLC patients (37) . In the present study, there was an association between the platelet count and DFS or OS time according to Kaplan-Meier analysis and log-rank test. The DFS and OS times were significantly longer in patients with a normal platelet count than in those with thrombocytosis. Usually, lymphatic metastasis is a strong prognostic factor for NSCLC. The present study showed that there was no association between the platelet count and survival whether the lymph node metastasis was present or not. Therefore, platelet count may not be a useful biomarker for predicting lymph node status.
There are several limitations to the present study, which should be taken into consideration. The study was retrospective and information on post-treatment recurrence was insufficient. However, the major positive factor of the study was the large population of NSCLC samples, which assisted in avoiding bias and offsetting the heterogeneity. A prospective study is also required to determine the prognostic value of MRP1 expression and platelet count.
In conclusion, MRP1 expression and platelet count are valuable independent prognostic biomarkers for survival in patients with operable NSCLC, and they should be assessed in patients with NSCLC in future studies to confirm their prognostic significance. Large prospective studies are required to validate these findings.
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